In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deep Breeze's vibration-based pulmonary imaging system:

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) marketing clearance for the VRIXP, an imaging system developed by Israeli firm Deep Breeze. The product employs vibration response imaging (VRI) technology, a noninvasive, radiation-free system that uses lung sounds to create dynamic images of the lungs. It records the sounds of the patient's breath, using sensors applied to the back, and then uses an algorithm to convert these data into images. The firm contends that changes in tissue composition or airflow alter the way in which sounds within the lungs vibrate. Or-Akiva-based Deep Breeze plans to launch VRIXP in the US at the 2007 CHEST meeting, to be held in Chicago in October. It received CE mark approval for sale in Europe in September 2005 (see Clinica No 1176, p 19).

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Topics

UsernamePublicRestriction

Register

MT049505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel